European Journal of Clinical Pharmacology

, Volume 72, Issue 1, pp 117–123 | Cite as

Off-label and unlicensed drug treatments in Neonatal Intensive Care Units: an Italian multicentre study

Pharmacoepidemiology and Prescription

Abstract

Purpose

The use of medicines among newborns admitted to intensive care units is characterized by a high prevalence of off-label/unlicensed use and a wide variability in the absence of international guidelines. A prospective cross-sectional study was organized with the aim to analyse drug prescriptions among all 107 Italian level III neonatal intensive care units.

Methods

An online questionnaire was used to collect detailed information for each newborn, and a classification was made about the license status of all prescriptions. In addition, prescriptions were analysed taking into account a practical guide prepared by the Italian Society of Neonatology (ISN).

Results

The 1-day survey (May–July 2014) regarded 220 newborn infants admitted to 36/107 Italian neonatal intensive care units: 191 prematures and 29 born at term. In total, 720 prescriptions (corresponding to 79 different drugs) were analysed: 191 (26.5 %) followed the terms of the product license, 529 (73.5 %) were off-label or unlicensed: 193/220 newborns (87.7 %) received at least one off-label/unlicensed prescription. Antiinfectives were the most common medicine used, followed by respiratory drugs and antianaemics; in an off-label manner, the most common was cardiovascular and central nervous system (CNS) drugs, gastrointestinals and antiinfectives. The most common categories of off-label use were age (34.4 %) and dosing frequency (20.6 %). Compared to ISN practical guide, prescriptions adhered more frequently to indications (100 % for ampicillin/sulbactam, >80 % for ampicillin, fluconazole, fentanyl, ranitidine and vancomicin).

Conclusions

Our results confirm the high prevalence of off-label/unlicensed drug use in the neonatal population and underline a better adherence to indications based on clinical practice, suggesting the need to update information contained in the data sheets of medicines.

Keywords

Newborn Medicines Off-label use Variability 

References

  1. 1.
    Cuzzolin L (2014) Variability in drug use among newborns admitted to NICUs: a proposal for a European multicentre study. J Pediatr Neonatal Individual Med 3(1), e030122. doi:10.7363/030122 Google Scholar
  2. 2.
    Van Riet-Nales DA, de Jager KE, Schobben AF, Egberts TC, Rademaker CM (2011) The availability and age-appropriateness of medicines authorized for children in the Netherlands. Br J Clin Pharmacol 72:465–473. doi:10.1111/j.1365-2125.2011.03982.x PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Mason J, Pirmohamed M, Nunn T (2012) Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature. Eur J Clin Pharmacol 68:21–28. doi:10.1007/s00228-011-1097-1 PubMedCrossRefGoogle Scholar
  4. 4.
    Conroy S (2011) Association between licence status and medication errors. Arch Dis Child 96:305–306. doi:10.1136/adc.2010.191940 PubMedCrossRefGoogle Scholar
  5. 5.
    Agostino R, Braguglia A, Caccamo ML, Dotta A, Massenzi L, Messner H, Sorrentino E (2009) Farmacoterapia neonatale: guida pratica (con software interattivo). Biomedia Ed, MilanGoogle Scholar
  6. 6.
    American Academy of Pediatrics (2014) Policy statement: off-label use of drugs in children. Pediatrics 133(3):563–567. doi:10.1542/peds.2013-4060 CrossRefGoogle Scholar
  7. 7.
    Olski TM, Lampus SF, Gherarducci G, Saint Raymond A (2011) Three years of paediatric regulation in the European Union. Eur J Clin Pharmacol 67:245–252. doi:10.1007/s00228-011-0997-4 PubMedCrossRefGoogle Scholar
  8. 8.
    EMA document (2013) Successes of the paediatric regulation after 5 years. EMA/250577/2013. Available at: http://www.ema.europa.eu/ema/index.jsp?curl-pages/news_and_events/news/2013/06/news_detail_001823.jsp&mid-WC0b01ac058004d5c1 Accessed 19 Aug 2013
  9. 9.
    Pansieri C, Bonati M, Choonara I, Jacqz-Aigrain E (2014) Neonatal drug trials: impact of EU and US paediatric regulations. Arch Dis Child Fetal Neonatal Ed (online first). doi:10.1136/archdischild-2013-305900 Google Scholar
  10. 10.
    Cuzzolin L (2014) Off-label drug in the newborn. J Pediatr Neonat Individual Med 3(2), e030224. doi:10.7363/030224 Google Scholar
  11. 11.
    Conroy S, McIntyre J, Choonara I (1999) Unlicensed and off label drug use in neonates. Arch Dis Child Fetal Neonat Ed 80:F142–F145. doi:10.1136/fn.80.2.F142 CrossRefGoogle Scholar
  12. 12.
    Avenel S, Bomkratz A, Dassieu G, Janaud JC, Danan C (2000) The incidence of prescriptions without marketing product license in a neonatal intensive care unit. Arch Pediatr 7:143–147. doi:10.1016/S0929-693x(00)88083-5 PubMedCrossRefGoogle Scholar
  13. 13.
    T’ Jong GW, Vulto AG, De Hoog M, Schimmel JM, Tibboel D, Van den Anker JN (2001) A survey of the use of off-label and unlicensed drugs in a Dutch Children’s Hospital. Pediatrics 108:1089–1093. doi:10.1542/peds.108.5.1089 CrossRefGoogle Scholar
  14. 14.
    Lopez-Martinez R, Cabanas Poy MJ, Oliveras Arenas M, Clemente Bautista S (2005) Utilizacion de medicamentos en una UCI neonatal: studio prospectivo. Farm Hosp 29:26–29PubMedCrossRefGoogle Scholar
  15. 15.
    Di Paolo ER, Stoetter H, Cotting J, Frey P, Gehri M, Beck-Popovic M, Tolsa J, Fanconi S, Pannatier A (2006) Unlicensed and off-label drug use in a Swiss paediatric university hospital. Swiss Med Wkly 136:218–222PubMedGoogle Scholar
  16. 16.
    Prandstetter C, Tamesberger M, Wagner O, Weissensteiner M, Wiesinger-Eidenberger G, Weidinger I, Lechner E (2009) Medical prescriptions to premature and newborn infants in an Austrian neonatal intensive care unit. Klin Pediatr 221:312–317. doi:10.1055/s-0029-1220903 CrossRefGoogle Scholar
  17. 17.
    Lindell-Osuagwu L, Korhonen MJ, Saano S, Helin-Tanninen M, Naaranlahti T, Kokki H (2009) Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature. J Clin Pharm Ther 34:277–287. doi:10.1111/j.1365-2710.2008.01005.x PubMedCrossRefGoogle Scholar
  18. 18.
    Neubert A, Lukas K, Leis T, Dormann H, Brune K, Rascher W (2010) Drug utilization on a preterm and neonatal intensive care unit in Germany: a prospective, cohort-based analysis. Eur J Clin Pharmacol 66:87–95. doi:10.1007/s00228-009-0722-8 PubMedCrossRefGoogle Scholar
  19. 19.
    Nguyen KA, Claris O, Kassai B (2011) Unlicensed and off-label drug use in a neonatal unit in France. Acta Paediatr 100:615–617. doi:10.1111/j.1651-2227.2010.02103.x PubMedCrossRefGoogle Scholar
  20. 20.
    Lass J, Käär R, Jõgi K, Varendi H, Metsvaht T, Lutsar I (2011) Drug utilization pattern and off-label use of medicines in Estonian neonatal units. Eur J Clin Pharmacol 67:1263–1271. doi:10.1007/s00228-011-1072-x PubMedCrossRefGoogle Scholar
  21. 21.
    Kimland E, Nydert P, Odlind V, Böttiger Y, Lindemalm S (2012) Paediatric drug use with focus on off-label prescriptions at Swedish hospitals—a nationwide study. Acta Paediatr 101:772–778. doi:10.1111/j.1651-2227.2012.02656.x PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Oguz SS, Kanmaz HG, Dilmen U (2012) Off-label and unlicensed drug use in neonatal intensive care units in Turkey: the old-inn study. Int J Clin Pharm 34:136–141. doi:10.1007/s11096-011-9604-0 PubMedCrossRefGoogle Scholar
  23. 23.
    Palčevski G, Skočibušić N, Vlahović-Palčevski V (2012) Unlicensed and off-label drug use in hospitalized children in Croatia: a cross-sectional survey. Eur J Clin Pharmacol 68:1073–1077. doi:10.1007/s00228-012-1221-x PubMedCrossRefGoogle Scholar
  24. 24.
    Kieran EA, O’Callaghan N, O’Donnell CPF (2014) Unlicensed and off-label drug use in an Irish neonatal intensive care unit: a prospective cohort study. Acta Paediatr 103:e139–e142. doi:10.1111/apa.12541 PubMedCrossRefGoogle Scholar
  25. 25.
    Lindell-Osuagwu L, Hakkarainen M, Sepponen K, Vainio K, Naaranlahti T, Kokki H (2014) Prescribing for off-label use and unauthorized medicines in three paediatric wards in Finland, the status before and after the European Union Paediatric Regulation. J Clin Pharm Ther 39:144–153. doi:10.1111/jcpt.12119 PubMedCrossRefGoogle Scholar
  26. 26.
    Dell’Aera M, Gasbarro AR, Padovano M, Laforgia N, Capodiferro D, Solarino B, Quaranta R, Dell’Erba AS (2007) Unlicensed and off-label use of medicines at a neonatology clinic in Italy. Pharm World Sci 29:361–367. doi:10.1007/s11096-006-9081-z PubMedCrossRefGoogle Scholar
  27. 27.
    Dessì A, Salemi C, Fanos V, Cuzzolin L (2010) Drug treatments in a neonatal setting: focus on the off-label use in the first month of life. Pharm World Sci 32:120–124. doi:10.1007/s11096-009-9356-2 PubMedCrossRefGoogle Scholar
  28. 28.
    Laforgia N, Nuccio MM, Schettini F, Dell’Aera M, Gasbarro AR, Dell’Erba A, Solarino B (2014) Off-label and unlicensed drug use among neonatal intensive care units in Southern Italy. Pediatr Int 56:57–59. doi:10.1111/ped.12190 PubMedCrossRefGoogle Scholar
  29. 29.
    Porta A, Esposito S, Menson E, Spyridis N, Tsolia M, Sharland M, Principi N (2010) Off-label antibiotic use in children in three European countries. Eur J Clin Pharmacol 66(9):919–927. doi:10.1007/s00228-010-0842-1 PubMedCrossRefGoogle Scholar
  30. 30.
    Manzoni P, Mostert M, Jacqz-Aigrain E, Farina D (2009) The use of fluconazole in neonatal intensive care units. Arch Dis Child 94:983–987. doi:10.1136/ adc.2008.154385 PubMedCrossRefGoogle Scholar
  31. 31.
    Benjamin DK, Hudak ML, Duara S et al (2014) Effect of fluconazole prophylaxis on candidiasis and mortality in premature infants: a randomized clinical trial. JAMA 311(17):1742–1749. doi:10.1001/jama.2014.2624 PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Pansieri C, Pandolfini C, Jacqz-Aigrain E, van den Anker J, Bonati M (2015) Fluconazole prophylaxis in neonates. Arch Dis Child 100(1):75–76. doi:10.1136/ archdischild-2014-306771 PubMedCrossRefGoogle Scholar
  33. 33.
    Pappas PG, Kauffman CA, Andes D et al (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503–535. doi:10.1086/596757 PubMedCrossRefGoogle Scholar
  34. 34.
    Kaguelidou F, Pandolfini C, Manzoni P, Choonara I, Bonati M, Jacqz-Aigrain E (2012) European survey on the use of prophylactic fluconazole in neonatal intensive care units. Eur J Pediatr 171:439–445. doi:10.1007/s00431-011-1565-8 PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Pandolfini C, Sequi M, Manzoni P, Bonati M (2013) The use of ciprofloxacin and fluconazole in Italian neonatal intensive care units: a nationwide survey. BMC Pediatr 13:5. doi:10.1186/1471-2431-13-5 PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Malcom WF, Cotton CM (2012) Metoclopramide, H2 blockers, and proton pump inhibitors: pharmacotherapy for gastroesophageal reflux in neonates. Clin Perinatol 39(1):99–109. doi:10.1016/j.clp.2011.12.015 CrossRefGoogle Scholar
  37. 37.
    Laughon MM, Avant D, Tripathi N, Hornik CP, Cohen-Wolkowiez M, Clark RH, Smth PB, Rodriguez W (2014) Drug labelling and exposure in neonates. JAMA Pediatr 168(2):130–136. doi:10.1001/jamapediatrics.2013.4208 PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Terrin G, Passariello A, De Curtis M, Manguso F, Salvia G, Lega L, Messina F, Paludetto R, Berni Canani R (2012) Ranitidine is associated with infections, necrotizing enterocolitis, and fatal outcome in newborns. Pediatrics 129:e40–e45. doi:10.1542/peds.2011-0796 PubMedCrossRefGoogle Scholar
  39. 39.
    Tighe M, Afzal NA, Bevan A, Hayen A, Munro A, Beattie RM (2014) Pharmacological treatment of children with gastro-oesophageal reflux. Cochrane Database Syst Rev 11, CD008550. doi:10.1002/14651858.CD008550.pub2 PubMedGoogle Scholar
  40. 40.
    Haiden N, Klebermass K, Cardona F, Schwindt J, Berger A, Kohlhauser-Vollmuth C, Jilma B, Pollak A (2006) A randomized, controlled trial of the effects of adding vitamin B12 and folate to erythropoietin for the treatment of anemia of prematurity. Pediatrics 118:180–188. doi:10.1542/peds.2005-2475 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of Diagnostics & Public Health-Section of PharmacologyUniversity of Verona, Policlinico G.B. RossiVeronaItaly
  2. 2.Fatebenefratelli-ricercaRomeItaly

Personalised recommendations